Purposes: To identify potent DNA methylation candidates that could predict response to temozolomide (TMZ) in glioblastomas (GBMs) that do not have glioma‐CpGs island methylator phenotype (G‐CIMP) but have an unmethylated promoter of O‐6‐methylguanine‐DNA methyltransferase (unMGMT).Methods: The discovery‐validation approach was planned incorporating a series of G‐CIMP−/unMGMT GBM cohorts with DNA methylation microarray data and clinical information, to construct multi‐CpG prediction models. Different bioinformatic and experimental analyses were performed for biological exploration.Results: By analyzing discovery sets with radiotherapy (RT) plus TMZ versus RT alone, we identified a panel of 64 TMZ efficacy‐related CpGs, from which a 10‐CpG risk signature was further constructed. Both the 64‐CpG panel and the 10‐CpG risk signature were validated showing significant correlations with overall survival of G‐CIMP−/unMGMT GBMs when treated with RT/TMZ, rather than RT alone. The 10‐CpG risk signature was further observed for aiding TMZ choice by distinguishing differential outcomes to RT/TMZ versus RT within each risk subgroup. Functional studies on GPR81, the gene harboring one of the 10 CpGs, indicated its distinct impacts on TMZ resistance in GBM cells, which may be dependent on the status of MGMT expression.Conclusions: The 64 TMZ efficacy‐related CpGs and in particular the 10‐CpG risk signature may serve as promising predictive biomarker candidates for guiding optimal usage of TMZ in G‐CIMP−/unMGMT GBMs.
Inflammatory response following central nervous system (CNS) injury is a significant, multifaceted process that requires further studies. Microglia and macrophages play key roles in CNS inflammation. However, it is still undefined what activity PD-1 plays in M1 polarization and what mechanisms PD-1 regulates the polarization of microglia and macrophages. This study was design to determine whether PD-1 influences M1 polarization of microglia and macrophages and explore PD-1 regulatory mechanisms in M1 polarization using the model mouse and proteomics analysis. It applied six newborn and sixty 6-8 week-old C57BL/6 mice, sixty PD-1 knockout (KO) mice, sixty PD-L1 KO mice, and fifteen PD-1 over-expressed mice. Our studies have shown that programmed death-1 (PD-1) is upregulated in microglia and macrophages in spinal cord injury (SCI), and polarized stimulation induces the expression of PD-1 in cultured microglia and macrophages. We have also observed that following SCI in a PD-1 KO model mouse, there is an increase in M1 polarization of macrophages. PD-1 and PD-L1 were upregulated with M1 polarization in peritoneal macrophages, Raw 264.7 and cerebral cortex-derived microglia, and M1 polarization was inhibited by PD-1 and PD-L1 through STAT1/NF-κB and Akt/mTOR signaling pathways in bone marrow-derived macrophages of PD-1 KO and PD-L1 KO mice. This study supported that PD-1/PD-L1 inhibits M1 polarization of microglia and macrophages through STAT1/NF-κB and Akt/mTOR signaling pathways. PD-1 regulated M1 polarization could be a key clinical target of novel immune-focused therapeutic strategies for CNS injury and inflammatory response.
Objective. Alterations in the methylation state of pseudogenes may serve as clinically useful biomarkers of glioblastomas (GBMs) that do not have glioma-CpG island methylator phenotype (G-CIMP). Methods. Non-G-CIMP GBM datasets were included for evaluation, and a RISK-score signature was determined from the methylation state of pseudogene loci. Both bioinformatic and experimental analyses were performed for biological validation. Results. By integrating clinical information with DNA methylation microarray data, we screened a panel of eight CpGs from discovery cohorts of non-G-CIMP GBMs. Each CpG could accurately and independently predict the prognosis of patients under a treatment regime that combined radiotherapy (RT) and temozolomide (TMZ). The 8-CpG signature appeared to show opposite prognostic correlations between patients treated with RT/TMZ and those treated with RT monotherapy. The analyses further indicated that this signature had predictive value for TMZ efficacy because different survival benefits between RT/TMZ and RT therapies were observed in each risk subgroup. The incorporation of other risk factors, such as age and O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, with our pseudogene methylation signature could provide precise risk classification. In vitro experimental data revealed that two locus-specific pseudogenes (ZNF767P and CLEC4GP1) may modulate TMZ resistance via distinct mechanisms in GBM cells. Conclusion. The biologically and clinically relevant RISK-score signature, based on pseudogene methylation loci, may offer information for predicting TMZ responses of non-G-CIMP GBMs, that is independent from, but complementary to, MGMT-based approaches.